Key result
Metabolic syndrome increased the risk of long-term all-cause mortality and cardiovascular death in patients with acute coronary syndrome after complete revascularization.
Why the study?
Does metabolic syndrome increase the risk of long-term mortality in patients with acute coronary syndrome who underwent complete revascularization?
Cohort (n=384)
No
Does metabolic syndrome increase the risk of long-term mortality in patients with acute coronary syndrome who underwent complete revascularization?
Metabolic syndrome is a significant predictor of long-term all-cause and cardiovascular mortality in patients with acute coronary syndrome undergoing complete revascularization.
Answers are grounded in this paper and cite their sources.
Metabolic syndrome was associated with higher long-term mortality after ACS revascularization; hypothesis-generating and should not yet change practice.
BACKGROUND: Metabolic syndrome (MetS) is a risk factor and prognosticator for ischemic heart disease, but its actual effect on long-term mortality after acute coronary syndrome (ACS) remains unknown. METHODS AND RESULTS: All-cause death and cardiovascular death were investigated among patients with ACS upon admission who underwent complete revascularization by either percutaneous coronary intervention or bypass surgery between 1984 and 1992. MetS was defined according to the NCEP/ATPIII criteria modified for waist circumference. From among 1,836 patients who underwent complete revascularization during the study period, 384 (21.0%) with ACS were enrolled, of whom 163 (42.5%) had MetS. During a mean follow-up of 10.4 +/-3.4 years, the total number of deaths was 83 (21.6%), of which 38 (9.9%) were from cardiovascular causes. Cox proportional hazard analysis revealed that MetS increased the risk of mortality by a ratio of 1.62 (95% confidence interval (CI) 1.01-2.59, P=0.046) and of cardiovascular death by 2.40 (95%CI 1.16-4.94, P=0.018) in patients with ACS. CONCLUSIONS: MetS is a powerful determinant of long-term all-cause and cardiovascular death after ACS. Furthermore, MetS and ACS might jointly exacerbate poor long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Dohi et al. (2009) conducted a cohort in Acute Coronary Syndrome (n=384). Metabolic syndrome vs. Absence of metabolic syndrome was evaluated on All-cause mortality (HR 1.62, 95% CI 1.01-2.59, p=0.046). Metabolic syndrome increased the risk of long-term all-cause mortality and cardiovascular death in patients with acute coronary syndrome after complete revascularization.
Synapse has enriched 10 related papers. Consider them for comparative context: